Two years later, in phase 2, a dose-escalation trial in DMD patients under the selection of amenable deletions achieved no drug-related adverse events while achieving a significant observation of dose-dependent dystrophin expression (NCT00844597) [16]. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.